Emerson Electric (EMR) stock is holding steady as investors assess its core industrial automation and software businesses. The company, traded on the NYSE, serves industrial customers with automation, control, and software tools, positioning it as a play on modernization spending in various industries. The key question for investors is how the recurring software and service revenue balances the more cyclical parts of its industrial base.

Lululemon Athletica has launched its Studio Membership, providing app-based fitness classes like strength, cardio, and yoga for under $15 a month in the US. This move signifies Lululemon's strategic shift in its connected fitness approach, moving away from proprietary hardware like the discontinued Studio Mirror to focus on digital services. The membership aims to integrate with customers' existing workout habits, leveraging the brand's apparel ecosystem and offering studio-quality content to compete with services like Apple Fitness+ and the Peloton App.

Steris plc operates as a global provider of infection prevention and sterilization solutions for healthcare and life science customers. The company offers a combination of equipment, consumables, and services tailored to hospitals, ambulatory surgery centers, laboratories, and pharmaceutical industries. Its business model addresses critical needs in maintaining sterile environments, supporting medical procedures, and ensuring compliance, positioning it to benefit from growing demands in patient safety and healthcare infrastructure worldwide.

Everest Re Group (EG) stock has hit a new 52-week high at $368.32, with a market capitalization of $14.6 billion and a P/E ratio of 7.5. InvestingPro analysis suggests the stock is undervalued, and it has delivered a 10.4% total return over the past year. Recent analyst updates and a dividend announcement also highlight the company's strategic adjustments and positive outlook.

Genuine Parts (GPC) saw its stock rise by 13% following a report that O'Reilly Automotive (ORLY) submitted a cash bid for its auto-parts division. This potential transaction could value the auto-parts arm at $10 billion or more. Conversely, O'Reilly Automotive's stock declined by 4.4% on the news.

Leidos Holdings Inc. (LDOS) is a U.S.-based science and technology company primarily serving government clients with defense, intelligence, and civil solutions. The company's business model relies on multi-year contracts, mission-critical systems integration, and specialized technical services, with a significant portion of its revenue derived from U.S. federal agencies. Leidos is positioned to capitalize on long-term trends like digital transformation in government, rising cybersecurity demand, and modernization of command-and-control infrastructure, making contract pipeline visibility and execution key for investors.

Goldman Sachs recently issued callable fixed-rate medium-term notes and was reclassified into Russell's value and defensive indices, suggesting a shift in its investment identity. This move reinforces the perception of Goldman Sachs as a more mature, capital-intensive company, despite analyst concerns about fintech disruption. The reclassification impacts both equity and fixed-income investors, highlighting the company's evolving capital deployment and funding strategies.

Thymmune Therapeutics has been acquired by United Therapeutics for $140 million. This acquisition, which closed on Thursday, integrates Thymmune's thymus cell therapy platform with United Therapeutics' focus on lung disease treatments and pig-to-human transplant research. The deal was reported by the Washington Business Journal.

Shares of medical device company ResMed (RMD) jumped 3.7% after being added to Goldman Sachs' APAC Conviction List, signaling renewed confidence in the company's growth trajectory ahead of its Q4 fiscal 2026 results. This positive movement comes despite a recent downgrade by Morgan Stanley due to concerns about profit margins, competition, and the impact of GLP-1 weight-loss drugs on sleep apnea treatment demand. ResMed's stock is still down 14.5% year-to-date and 28.8% from its 52-week high.

Shares of aerospace and defense company Raytheon Technologies (RTX) rose 3.4% after its Raytheon business secured a $1.1 billion contract from the U.S. Navy for AIM-9X Block II missiles. This contract, along with increased production capacity to 2,500 missiles annually, reinforced a bullish outlook from Wall Street analysts. The stock is up 6.2% year-to-date and is trading near its 52-week high, with significant returns for long-term investors.